These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 33016783)

  • 21. Safety and pharmacokinetics of a new biosimilar trastuzumab (HL02): a Phase I bioequivalence study in healthy Chinese men.
    Zhang H; Liu T; Wu M; Wei H; Li C; Li X; Liu J; Chen H; Ding Y; Liu L
    Expert Opin Biol Ther; 2022 Feb; 22(2):179-186. PubMed ID: 33616478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized pharmacokinetic/pharmacodynamic study comparing the bioequivalence of potential biosimilar candidate P044 with reference medicine in healthy volunteers.
    Raykova E; Farmahini Farahani M; Ivanova S; Azhdarzadeh M
    Expert Opin Biol Ther; 2022 Feb; 22(2):235-243. PubMed ID: 34405742
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Randomized Phase I Pharmacokinetic Study Comparing Biosimilar Candidate SB3 and Trastuzumab in Healthy Male Subjects.
    Pivot X; Curtit E; Lee YJ; Golor G; Gauliard A; Shin D; Kim Y; Kim H; Fuhr R
    Clin Ther; 2016 Jul; 38(7):1665-1673.e3. PubMed ID: 27368117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab.
    Alexeev SM; Khorinko AV; Mukhametshina GZ; Shelepen KG; Burdaeva ON; Kulik SA; Satheesh CT; Srivastava K; Vikranth M; Kryukov F; Paltusova AN; Shustova MS; Ivanov RA
    BMC Cancer; 2020 Aug; 20(1):783. PubMed ID: 32819305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIREĀ®-PK) in healthy subjects.
    Wynne C; Altendorfer M; Sonderegger I; Gheyle L; Ellis-Pegler R; Buschke S; Lang B; Assudani D; Athalye S; Czeloth N
    Expert Opin Investig Drugs; 2016 Dec; 25(12):1361-1370. PubMed ID: 27813422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx
    Yao F; Wang C; Ding J; Zhang Q; Zheng L; Zhang Q; Yang T; Zhang X; Shan Y; Hou S; Wang H; Zhou R; Hu W
    Drug Des Devel Ther; 2024; 18():3891-3901. PubMed ID: 39224901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, double-blind, parallel-group phase I study comparing the pharmacokinetics, safety, and immunogenicity of LY01008, a candidate bevacizumab biosimilar, with its reference product AvastinĀ® in healthy Chinese male subjects.
    Zhou R; Yang J; Liu Y; Zhang Q; Lu C; Tang K; Li X; Tang W; Gao E; Wu C; Dou C; Hu W
    Expert Opin Biol Ther; 2022 Feb; 22(2):263-269. PubMed ID: 34913787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjects.
    Hanes V; Chow V; Pan Z; Markus R
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):899-905. PubMed ID: 30269275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects.
    Hettema W; Wynne C; Lang B; Altendorfer M; Czeloth N; Lohmann R; Athalye S; Schliephake D
    Expert Opin Investig Drugs; 2017 Aug; 26(8):889-896. PubMed ID: 28651442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Randomized, Double-Blind, Parallel-Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects.
    Cao G; Yu J; Wu J; Wang J; Xue Y; Yang X; Zhang J
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):317-325. PubMed ID: 32463599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males.
    Cho SH; Han S; Ghim JL; Nam MS; Yu S; Park T; Kim S; Bae J; Shin JG
    BioDrugs; 2019 Apr; 33(2):173-181. PubMed ID: 30850957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic similarity study comparing the biosimilar candidate, LY05008, with its reference product dulaglutide in healthy Chinese male subjects.
    Zhang Q; Sun C; Wu J; Wu J; Zhang X; Liu Y; Dou C; Qin H; Zhang Q; Zhou R; Hu W
    Expert Opin Biol Ther; 2023; 23(8):727-735. PubMed ID: 36880118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of teriparatide biosimilar with EU- and US-approved teriparatide reference products in healthy men and postmenopausal women.
    Fenwick S; Vekariya V; Patel R; Hajela P; Modi K; Kale P; Nath A
    Osteoporos Int; 2023 Jan; 34(1):179-188. PubMed ID: 36287230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparing the pharmacokinetics, safety, and immunogenicity of HLX02 to US- and EU-approved trastuzumab in healthy Chinese male subjects: A Phase I, randomized, double-blind, parallel-group study.
    Zhou W; Wang M; Yu Y; Wang J; Wu Y; Yang G; Yu H; Li J; Zhou L; Zhang Q
    Expert Opin Biol Ther; 2023; 23(8):717-725. PubMed ID: 36843059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double-blind, parallel-controlled, phase 1 study.
    Zhang H; Wu M; Sun J; Zhu X; Li C; Ding Y; Zhang X; Chai K; Li X
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00733. PubMed ID: 33682358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects.
    Yang J; Lin L; Long Q; Zhang Q; Sun G; Zhou L; Wang Q; Zhu J; Li F; Hu W
    BioDrugs; 2022 May; 36(3):393-409. PubMed ID: 35594017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects.
    Hanes V; Chow V; Zhang N; Markus R
    Cancer Chemother Pharmacol; 2017 May; 79(5):881-888. PubMed ID: 28341959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I study comparing the biosimilarity of the pharmacokinetics and safety of recombinant humanized anti-vascular endothelial growth factor monoclonal antibody injection with Avastin
    Li H; Zhao X; Xie J; Zhu X; Su Y; He C; Ding J; Zhu M; Xu Y; Wang Y; Shan R; Liu B; Ding Y; Liu Y; Zhou H; Xie Y
    BMC Pharmacol Toxicol; 2023 May; 24(1):36. PubMed ID: 37245022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Randomized Phase I Study Comparing the Pharmacokinetics of HD201, a Trastuzumab Biosimilar, With European Union-sourced Herceptin.
    Pivot X; Deslypere JP; Park LS; Kim MJ; Lee W; Lee J
    Clin Ther; 2018 Mar; 40(3):396-405.e4. PubMed ID: 29502805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, double-blind, single-dose study (LAVENDER) to assess the safety, tolerability, pharmacokinetics, and immunogenicity of a combined infusion of ABP 980 and pertuzumab in healthy subjects.
    Hanes V; Chow V; Stewart T; Puri A
    Cancer Chemother Pharmacol; 2021 Nov; 88(5):879-886. PubMed ID: 34355250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.